This graph shows the number of orphan designated drugs currently being developed by emerging therapeutic companies in the U.S., as of April 2019. As of this time, of the 612 non-oncologic orphan programs being developed, almost half were in Phase II of development.
Global therapeutic pipeline for non-oncology orphan drug programs by company 2019
Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Further Content: You might find this interesting as well
Statistics
- Total rare diseases funding by the National Institutes for Health 2013-2020
- Overview of rare diseases worldwide and in the U.S. as of 2016
- Share of primary Sjögren patients in the U.S. and EU using healthcare resources 2013
- Comorbidity in primary Sjögren's patients in the U.S. and EU 2015
- Share of primary Sjögren's patients in the U.S. and EU with impairments 2011-2013
- Italy: rare disease patients treated within clinical trials 2017, by disease
- Prevalence of selected rare diseases worldwide 2017
- Number of individuals with rare diseases in Spain 2016
- Expenses made by individuals affected by rare diseases in Spain 2016
- Share of family members who supported relatives with rare diseases in Spain 2016
- U.S. rare disease patient feelings as of 2015
- Italy: number clinical trials for rare diseases 2013-2017
- Enterprise value of top companies in non-oncology rare disease therapeutics 2017
- Italy: number of individuals affected by bleeding disorders 2016, by type and gender
- Top rare disease therapeutic companies enterprise value worldwide 2000-2017
- Dressings packaged for medical use: UK import value 2001-2018
- U.S. adults thinking the government should fund antibiotic development 2018
- Polyvalent immune globulin sales worldwide 1992-2014
- Distribution of paper and paperboard production in Finland 2015
- Global workforce analytic applications revenue by vendor 2012-2014
Biotechnology Innovation Organization. (May 31, 2019). Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019 [Graph]. In Statista. Retrieved December 07, 2019, from https://www.statista.com/statistics/597291/orphan-drug-pipeline-emerging-therapeutic-us-companies/
Biotechnology Innovation Organization. "Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019." Chart. May 31, 2019. Statista. Accessed December 07, 2019. https://www.statista.com/statistics/597291/orphan-drug-pipeline-emerging-therapeutic-us-companies/
Biotechnology Innovation Organization. (2019). Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019. Statista. Statista Inc.. Accessed: December 07, 2019. https://www.statista.com/statistics/597291/orphan-drug-pipeline-emerging-therapeutic-us-companies/
Biotechnology Innovation Organization. "Number of Non-oncology Orphan Designated Products Currently Being Developed Worldwide by Company Type as of April 2019." Statista, Statista Inc., 31 May 2019, https://www.statista.com/statistics/597291/orphan-drug-pipeline-emerging-therapeutic-us-companies/
Biotechnology Innovation Organization, Number of non-oncology orphan designated products currently being developed worldwide by company type as of April 2019 Statista, https://www.statista.com/statistics/597291/orphan-drug-pipeline-emerging-therapeutic-us-companies/ (last visited December 07, 2019)